Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.

Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.

Int J Behav Med. 2017 Mar 6. doi: 10.1007/s12529-017-9644-5. [Epub ahead of print]

PMID:
28265809
2.

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.

Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.

Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743.

3.

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.

Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K.

Invest New Drugs. 2016 Jun;34(3):347-54. doi: 10.1007/s10637-016-0347-6. Epub 2016 Mar 22.

4.

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.

Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.

Breast Cancer. 2016 May;23(3):329-42. doi: 10.1007/s12282-016-0670-y. Epub 2016 Feb 24. No abstract available.

PMID:
26910609
5.

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.

Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.

Invest New Drugs. 2016 Jun;34(3):394-6. doi: 10.1007/s10637-016-0329-8. Epub 2016 Feb 9.

PMID:
26856856
6.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Oncotarget. 2016 Jan 19;7(3):3453-60. doi: 10.18632/oncotarget.6498.

7.

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group..

Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27.

PMID:
26617202
8.

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.

Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K.

Anticancer Drugs. 2016 Mar;27(3):251-3. doi: 10.1097/CAD.0000000000000317.

PMID:
26575001
9.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.

PLoS One. 2015 May 8;10(5):e0121891. doi: 10.1371/journal.pone.0121891. eCollection 2015 May 8.

10.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.

Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9.

11.

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K.

Br J Cancer. 2015 Mar 3;112(5):819-24. doi: 10.1038/bjc.2015.10. Epub 2015 Feb 5.

12.

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.

Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K.

Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.

13.

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K.

J Thorac Oncol. 2015 Feb;10(2):346-52. doi: 10.1097/JTO.0000000000000395.

14.

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.

Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society..

Breast Cancer. 2015 Jan;22(1):5-15. doi: 10.1007/s12282-014-0563-x. Epub 2014 Sep 9. No abstract available.

PMID:
25200171
15.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.

Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014 Aug 8.

16.

Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.

Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K.

PLoS One. 2014 Jul 14;9(7):e101902. doi: 10.1371/journal.pone.0101902. eCollection 2014 Jul 14.

17.

Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T.

Anticancer Res. 2014 Jul;34(7):3583-8.

PMID:
24982373
18.

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K.

Invest New Drugs. 2014 Oct;32(5):946-54. doi: 10.1007/s10637-014-0112-7. Epub 2014 May 31.

PMID:
24875132
19.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
20.

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.

Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.

Oncotarget. 2014 Feb 28;5(4):1062-70.

Supplemental Content

Loading ...
Support Center